Condition
aGVHD clinical trials and research
As of November 12, 2026, Find a Trial lists 4 aGVHD clinical trials that are recruiting, at sites in 2 countries (most in China (3), United States (1)). By phase: Phase 2 (3). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 2Countries
Newest aGVHD clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Gastric protection after transplant: switch from PPI to teprenone to see effects on GVHD | — | Hangzhou | Recruiting | Aug 28, 2026 |
| BPC2001 to prevent acute graft-versus-host disease after haploidentical stem cell transplant | Phase 2 | Beijing, Beijing Municipality and 1 other locations | Recruiting | Nov 24, 2025 |
| Gecacitinib with Corticosteroid as First‑Line Therapy for Grade II–IV Acute GVHD | Phase 2 | Suzhou, Jiangsu | Recruiting | Sep 22, 2025 |
| Combining an unmodified family (haplo‑identical) donor graft with cord blood for transplant | Phase 2 | Cleveland, Ohio | Recruiting | Apr 1, 2025 |
All recruiting trials (4)
-
Gastric protection after transplant: switch from PPI to teprenone to see effects on GVHD
This trial tests whether switching from a proton pump inhibitor to teprenone after allogeneic HSCT changes the risk of acute graft-versus-host disease in patients with hematologic cancers.
-
BPC2001 to prevent acute graft-versus-host disease after haploidentical stem cell transplant
This trial tests whether six weekly doses of BPC2001 given with standard care can prevent acute graft-versus-host disease in adults having haploidentical stem cell transplants.
-
Gecacitinib with Corticosteroid as First‑Line Therapy for Grade II–IV Acute GVHD
This study tests whether adding gecacitinib to standard corticosteroid therapy helps adults with newly diagnosed grade II–IV acute GVHD.
-
Combining an unmodified family (haplo‑identical) donor graft with cord blood for transplant
This trial will test whether giving an unmodified haplo‑identical donor graft followed by a cord blood graft with post‑transplant cyclophosphamide helps people with high‑risk AML, ALL, or MDS stay free of disease.
Related topics
Quick answers
How many aGVHD clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (3 trials), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.